Sorrento Therapeutics, Inc.
SRNEDelisted Apr 12, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000850261
Sorrento Therapeutics, Inc. was delisted on Apr 12, 2023; its insiders filed their last Form 4 on Mar 20, 2023; 224 institutions reported holding it in 13F filings for Q4 2022, worth $180.7M in total; Oaktree Capital was the only superinvestor holding it.
13F holders, Q2 2025
Institutional positions in Sorrento Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
SRNE is no longer listed, and 13F filings after Q4 2022 list far fewer holders. See Q4 2022
- Institutional holders
- 2
- −1 vs. Q1 2025
- Shares held
- 5.02K
- −1.05K (−17.3%) vs. Q1 2025
- Total value
- $6
- +$2 (+50.0%) vs. Q1 2025
- New holders
- 1
- 0 more added
- Sold out
- 2
- 0 more reduced
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SRNE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 5 | $70 |
| Q1 2026 | 4 | $380 |
| Q4 2025 | 5 | $82 |
| Q3 2025 | 4 | $20 |
| Q2 2025 | 2 | $6 |
| Q1 2025 | 4 | $4 |
| Q4 2024 | 5 | $66 |
| Q3 2024 | 4 | $287 |
| Q2 2024 | 5 | $826 |
| Q1 2024 | 7 | $704 |
| Q4 2023 | 9 | $13.9K |
| Q3 2023 | 9 | $6.42K |
| Q2 2023 | 9 | $26.1K |
| Q1 2023 | 34 | $1.58M |
| Q4 2022 | 224 | $180.7M |
| Q3 2022 | 233 | $260.2M |
| Q2 2022 | 229 | $308.5M |
| Q1 2022 | 235 | $301.7M |
| Q4 2021 | 234 | $432.2M |
| Q3 2021 | 221 | $657.9M |
| Q2 2021 | 212 | $750.9M |
| Q1 2021 | 231 | $641.4M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Sorrento Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Huntington National Bank | 5,001 | $6 | 0.00% | 00.0% | Unchanged |
| Financial Gravity Companies, Inc. | 18 | $0 | 0.00% | +18 | New |
| Vermillion Wealth Management, Inc. | 0 | $0 | 0.00% | −70−100.0% | Sold out |
| Flagship Wealth Advisors, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Sofos Investments, Inc. | – | – | – | – | Not filed |